Journal
NEUROPHARMACOLOGY
Volume 130, Issue -, Pages 54-61Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2017.11.042
Keywords
Alzheimer's disease; APPswe/PS1 Delta E9 mice; Saracatinib; AZD0530; Memantine; Namenda; Fyn kinase
Categories
Funding
- NIH [R01AG034924, RF1AG053000, R35NS097283, P50AG047270]
- Falk Medical Research Trust
Ask authors/readers for more resources
Alzheimer's disease remains without a disease-modifying therapy that improves symptoms after therapy withdrawal. Because no investigational agents have demonstrated disease-modifying effects clinically, we tested whether the Fyn inhibitor, saracatinib, provides persistent improvement in a transgenic model. Aged APPswe/PS1 Delta E9 mice were treated with saracatinib or memantine for 4 weeks and spatial memory improved to control levels. After drug washout, there was sustained rescue of both memory function and synapse density by saracatinib, but a loss of benefit from memantine. These data demonstrate a disease modifying persistent benefit for saracatinib in a preclinincal Alzheimer's model, and distinguish its action from that of memantine. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available